ANIP Rasio cepet ANI Pharmaceuticals

ANI Pharmaceuticals has optimized distribution through third-party contractors and US pharmacy chains. The quick ratio has reached a local peak, with the metric currently standing at 2.30. Growth is driven by the acquisition of legacy formulas and their production at automated FDA-certified plants. Environmental policy relies on standard effluent control and chemical waste disposal.

ANIP: Rasio jangkoan perantara ANI Pharma 04.07.2022 - 29.10.2026

anipharmaceuticals.com - rincian analitis lan metrik utama (ANIP)

- nilai pasar lan prakiraan target analis:

Bagan rega ANI Pharma|ANIP - Target konsensus

- data kapitalisasi pasar:

Kapitalisasi pasar ANI Pharma|ANIP - Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Nilai Akuntansi saben Saham ANI Pharmaceuticals|ANIP - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku anipharmaceuticals.com|ANIP - Aset Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas ANI Pharmaceuticals|ANIP - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal ANI Pharmaceuticals, Inc.|ANIP - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku ANI Pharma|ANIP - Utang jangka dawa|Utang jangka cendhak perusahaan ANI Pharmaceuticals|Rasio cepet anipharmaceuticals.com

- informasi bathi lan kelipatan valuasi:

ANIP - Bathi resik

Ringkesan analitik perusahaan:ANI Pharma - ANIP

Steady demand for generics at ANI Pharmaceuticals (ANIP) ensures a predictable cash flow, making the quick ratio a key indicator of operational autonomy. Analyzing this chart, an investor assesses the company's ability to meet its obligations using only cash and accounts receivable, excluding low-liquidity drug inventories, which confirms the issuer's financial stability during periods of expensive borrowed capital.

Analisis perusahaan pesaing